Justin Stebbing

Stebbing graduated from Trinity College, Oxford.{{cn|date=May 2024}} After completion of junior doctor positions in Oxford, he trained on the residency programme at The Johns Hopkins Hospital in the US, returning to London to continue his career at The Royal Marsden and then St Bartholomew's Hospitals. His PhD research investigated the interplay between the immune system and cancer including the role of viruses.{{Cite journal |last1=Stebbing |first1=Justin |last2=Gazzard |first2=Brian |last3=Douek |first3=Daniel C. |date=2004-04-29 |title=Where Does HIV Live? |url=http://www.nejm.org/doi/abs/10.1056/NEJMra032395 |journal=New England Journal of Medicine |language=en |volume=350 |issue=18 |pages=1872–1880 |doi=10.1056/NEJMra032395 |pmid=15115833 |issn=0028-4793}}{{Cite journal |title=Redirecting |url=https://linkinghub.elsevier.com/retrieve/pii/S1470204503011422 |access-date=2024-01-07 |journal=The Lancet. Oncology|date=2003 |doi=10.1016/S1470-2045(03)01142-2 |pmid=12850195 |last1=Stebbing |first1=J. |last2=Bower |first2=M. |volume=4 |issue=7 |pages=438–445 }} In 2007, he was appointed a senior lecturer, and then in 2009 a full professor, at Imperial College London.{{Cite web |title=Profile: Justin Stebbing |url=https://www.imperial.ac.uk/people/j.stebbing|publisher=Imperial}} In 2011, the National Institute for Health and Care Research awarded Stebbing its first Translational Professorship in Oncology, working on overcoming treatment resistance and targeted precision medicine approaches.{{Cite web |title=Current NIHR Research Professors |url=https://www.nihr.ac.uk/documents/current-nihr-research-professors/21758 |access-date=2024-01-07 |website=www.nihr.ac.uk |language=EN}}

Stebbing has published over 700 peer-reviewed papers{{Cite web |title=stebbing j - Search Results - PubMed |url=https://pubmed.ncbi.nlm.nih.gov/?term=stebbing+j |access-date=2024-01-07 |website=PubMed |language=en}} and has an h-index of 90 according to Google Scholar.{{Cite web |title=Justin Stebbing |url=https://scholar.google.com/citations?user=zYQDvoIAAAAJ&hl=en |access-date=2024-01-07 |website=scholar.google.com}}

Stebbing was an oncology professor at Imperial College London{{cite web|url=https://www.thetimes.com/uk/healthcare/article/doctor-god-justin-stebbing-avoids-being-struck-off-for-dishonesty-after-patients-rally-in-support-5g5hpswdv|title='Doctor God' Justin Stebbing avoids being struck off for dishonesty after patients rally in support|work=The Times|date=20 December 2021|access-date=23 May 2024|first=David|last=Brown}} and has gained a reputation for innovative treatments.{{cite web|url=https://www.medscape.co.uk/viewarticle/oncologist-denies-taking-too-many-patients-leading-failings-2021a1001wgg|publisher=Medscape UK|title=Oncologist Denies Taking on Too Many Patients Leading to Failings|date=5 July 2021|first=Ian|last=Leonard|access-date=23 May 2024}}

He is co-Editor-in-Chief of the journal Oncogene.{{cite web |title=About the Editors |url=https://www.nature.com/onc/editors |website=Oncogene }}

The charity Action Against Cancer was set up to support Stebbing's work.{{Cite web|url=https://www.aacancer.org/|title=Home | Action Against Cancer|website=www.aacancer.org|accessdate=28 March 2023}}{{failed verification|date=May 2024}}

Stebbing's research in cancer has included work on the molecular biology of solid tumours. His group identified LMTK3 as an oncogene and therapeutic target in breast cancer.{{cite journal |last1=Giamas |first1=Georgios |last2=Filipović |first2=Aleksandra |last3=Jacob |first3=Jimmy |last4=Messier |first4=Walter |last5=Zhang |first5=Hua |last6=Yang |first6=Dongyun |last7=Zhang |first7=Wu |last8=Shifa |first8=Belul Assefa |last9=Photiou |first9=Andrew |last10=Tralau-Stewart |first10=Cathy |last11=Castellano |first11=Leandro |last12=Green |first12=Andrew R. |last13=Coombes |first13=R. Charles |last14=Ellis |first14=Ian O. |last15=Ali |first15=Simak |last16=Lenz |first16=Heinz-Josef |last17=Stebbing |first17=Justin |title=Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer |journal=Nature Medicine |date=June 2011 |volume=17 |issue=6 |pages=715–719 |doi=10.1038/nm.2351 |pmid=21602804 |s2cid=5279914 }}{{psc|date=January 2022}} The team characterised the network of microRNAs induced by the estrogen receptor.{{cite journal |last1=Castellano |first1=Leandro |last2=Giamas |first2=Georgios |last3=Jacob |first3=Jimmy |last4=Coombes |first4=R. Charles |last5=Lucchesi |first5=Walter |last6=Thiruchelvam |first6=Paul |last7=Barton |first7=Geraint |last8=Jiao |first8=Long R. |last9=Wait |first9=Robin |last10=Waxman |first10=Jonathan |last11=Hannon |first11=Gregory J. |last12=Stebbing |first12=Justin |title=The estrogen receptor-α-induced microRNA signature regulates itself and its transcriptional response |journal=Proceedings of the National Academy of Sciences |date=21 August 2009 |volume=106 |issue=37 |pages=15732–15737 |doi=10.1073/pnas.0906947106 |pmid=19706389 |pmc=2747188 |bibcode=2009PNAS..10615732C |doi-access=free }}{{psc|date=January 2022}}

Stebbing has also worked on cancers caused by HIV and AIDS, including investigating immune reconstitution inflammatory syndrome in patients with Kaposi's Sarcoma.{{cite journal |last1=Bower |first1=M. |last2=Nelson |first2=M. |last3=Young |first3=A.M. |last4=Thirlwell |first4=C. |last5=Newsom-Davis |first5=T. |last6=Mandalia |first6=S. |last7=Dhillon |first7=T. |last8=Holmes |first8=P. |last9=Gazzard |first9=B.G. |last10=Stebbing |first10=J. |title=Immune Reconstitution Inflammatory Syndrome Associated With Kaposi's Sarcoma |journal=Journal of Clinical Oncology |date=1 August 2005 |volume=23 |issue=22 |pages=5224–5228 |doi=10.1200/JCO.2005.14.597 |pmid=16051964 |doi-access=free }}{{psc|date=January 2022}}

He has undertaken extensive work on biosimilars,{{Cite journal |title=CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial|url=https://linkinghub.elsevier.com/retrieve/pii/S1470-2045(17)30434-5 |access-date=2024-01-07 |journal=The Lancet Oncology|date=2017 |doi=10.1016/S1470-2045(17)30434-5 |pmid=28592386 |last1=Stebbing |first1=Justin |last2=Baranau |first2=Yauheni |last3=Baryash |first3=Valeriy |last4=Manikhas |first4=Alexey |last5=Moiseyenko |first5=Vladimir |last6=Dzagnidze |first6=Giorgi |last7=Zhavrid |first7=Edvard |last8=Boliukh |first8=Dmytro |last9=Stroyakovskii |first9=Daniil |last10=Pikiel |first10=Joanna |last11=Eniu |first11=Alexandru |last12=Komov |first12=Dmitry |last13=Morar-Bolba |first13=Gabriela |last14=Li |first14=Rubi K. |last15=Rusyn |first15=Andriy |last16=Lee |first16=Sang Joon |last17=Lee |first17=Sung Young |last18=Esteva |first18=Francisco J. |volume=18 |issue=7 |pages=917–928 |hdl=10044/1/52810 |hdl-access=free }}{{failed verification|date=May 2024}} cheaper versions of expensive biologic drugs designed to democratise access to these.{{Cite journal |last1=Stebbing |first1=Justin |last2=Baranau |first2=Yauheni |last3=Baryash |first3=Valery |last4=Moiseyenko |first4=Vladimir |last5=Boliukh |first5=Dmytro |last6=Antone |first6=Nicoleta |last7=Manikhas |first7=Alexey |last8=Chornobai |first8=Anatolii |last9=Park |first9=Taehong |last10=Baek |first10=Eric Hyungseok |last11=Lee |first11=Jaeyong |last12=Choi |first12=Jiin |last13=Kim |first13=Nahyun |last14=Ahn |first14=Keumyoung |last15=Lee |first15=Sang Joon |date=2023 |title=Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial |journal=Biodrugs |volume=37 |issue=3 |pages=433–440 |doi=10.1007/s40259-023-00582-w |issn=1173-8804 |pmid=36881323|pmc=10195725 }}

During the Covid-19 pandemic in early 2020, Stebbing used artificial intelligence to identify baricitinib as a potential drug treatment.{{cite journal |last1=Richardson |first1=Peter |last2=Griffin |first2=Ivan |last3=Tucker |first3=Catherine |last4=Smith |first4=Dan |last5=Oechsle |first5=Olly |last6=Phelan |first6=Anne |last7=Rawling |first7=Michael |last8=Savory |first8=Edward |last9=Stebbing |first9=Justin |title=Baricitinib as potential treatment for 2019-nCoV acute respiratory disease |journal=The Lancet |date=15 February 2020 |volume=395 |issue=10223 |pages=e30–e31 |doi=10.1016/S0140-6736(20)30304-4 |pmid=32032529 |pmc=7137985 }}{{psc|date=January 2022}}{{Cite journal |title=COVID-19: combining antiviral and anti-inflammatory treatments|journal=The Lancet Infectious Diseases|date=2020 |doi=10.1016/S1473-3099(20)30132-8 |pmid=32113509 |last1=Stebbing |first1=Justin |last2=Phelan |first2=Anne |last3=Griffin |first3=Ivan |last4=Tucker |first4=Catherine |last5=Oechsle |first5=Olly |last6=Smith |first6=Dan |last7=Richardson |first7=Peter |volume=20 |issue=4 |pages=400–402 |pmc=7158903 }} He led studies that showed that the drug reduced mortality in COVID-19 hospitalised patients with pneumonia, which led to the drug being authorised by the US Food and Drug Administration in October 2020 as an Emergency Use Authorization at first in combination with remdesivir, then alone.{{Cite web |title=Olumiant EUA FAQs {{!}} FDA |url=https://www.fda.gov/media/143825 |access-date=2024-02-14 |website=www.fda.gov}} Stebbing wrote a book, Witness to COVID, 2020, describing its discovery, trials, studies and approval.{{Cite book |title=Witness to Covid: 2020: The Diary of a Global Pandemic: Amazon.co.uk: Stebbing, Justin, Mukherjee, Siddhartha: 9781398112674: Books |id={{ASIN|1398112674|country=uk}} }}

Stebbing is part of a team that ran a phase 1/2 clinical trial using invariant natural killer T cells as an 'off-the-shelf' therapy in ventilated patients with acute respiratory distress syndrome (ARDS), the first time these cells have been used in the clinic.{{Cite journal |last1=Hammond |first1=Terese C. |last2=Purbhoo |first2=Marco A. |last3=Kadel |first3=Sapana |last4=Ritz |first4=Jerome |last5=Nikiforow |first5=Sarah |last6=Daley |first6=Heather |last7=Shaw |first7=Kit |last8=van Besien |first8=Koen |last9=Gomez-Arteaga |first9=Alexandra |last10=Stevens |first10=Don |last11=Ortuzar |first11=Waldo |last12=Michelet |first12=Xavier |last13=Smith |first13=Rachel |last14=Moskowitz |first14=Darrian |last15=Masakayan |first15=Reed |date=2024-02-06 |title=A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome |journal=Nature Communications |language=en |volume=15 |issue=1 |pages=974 |doi=10.1038/s41467-024-44905-z |pmid=38321023 |issn=2041-1723|pmc=10847411 |bibcode=2024NatCo..15..974H }}{{Cite news |last=Reporters |first=Telegraph |date=2024-02-07 |title=New cancer drug could improve prognosis for Covid patients |url=https://www.telegraph.co.uk/news/2024/02/07/new-cancer-drug-could-improve-prognosis-covid-patients/ |access-date=2024-02-14 |work=The Telegraph |language=en-GB |issn=0307-1235}}

Stebbing has worked on neurological therapies for patients with unmet medical needs who are treatment resistant or unresponsive to other existing medications.{{Cite press release |last=Corp |first=Equilibre Biopharmaceuticals |title=Equilibre Biopharmaceuticals Announces Positive Topline Results from Phase 2 Clinical Trial of EQU-001 (NCT05063877) for Safety, Tolerability and Preliminary Efficacy as Adjunctive Therapy for Focal Seizures in Adults with Epilepsy |url=https://www.prnewswire.com/news-releases/equilibre-biopharmaceuticals-announces-positive-topline-results-from-phase-2-clinical-trial-of-equ-001-nct05063877-for-safety-tolerability-and-preliminary-efficacy-as-adjunctive-therapy-for-focal-seizures-in-adults-with-epileps-301732789.html |access-date=2024-01-07 |website=www.prnewswire.com |language=en}}

Stebbing is a Fellow of the Royal College of Physicians, the American Society for Clinical Investigation{{Cite web|url=https://the-asci.org/controllers/asci/AsciProfileController.php?pid=501408|title = The American Society for Clinical Investigation}} and the Royal College of Pathologists.

As a clinician-scientist at Imperial College London, Stebbing practiced with the Imperial College Healthcare NHS Trust at Charing Cross Hospital and Hammersmith Hospital. He resigned his permanent position at Imperial in March 2022.

He has also practiced privately in Harley Street. Patients who experienced successful treatments in his care included Michael Parkinson and Lynda Bellingham.

As of 2024, he practices with the private Phoenix Hospital Group, where he specialises in a range of solid malignancies, including difficult cases with few conventional options.He is also working at the Lauriston Clinic in London.{{cite web | title=Professor Justin Stebbing | website=London Lauriston Clinic | date=2025-01-20 | url=https://www.llclinics.co.uk/consultant/professor-justin-stebbing/ | access-date=2025-04-17}}

In 2020, Stebbing was investigated by the General Medical Council over allegations that he failed to provide adequate care to eleven patients he had cared for between 2014 and 2017.{{Cite journal |last=Dyer |first=Clare |date=2020-09-15 |title=Leading oncologist faces GMC allegations of inappropriate treatment of dying patients |url=https://www.bmj.com/lookup/doi/10.1136/bmj.m3594 |journal=BMJ |volume=370 |language=en |pages=m3594 |doi=10.1136/bmj.m3594 |pmid=32933903 |issn=1756-1833}}{{Cite web |title=Leading Oncologist Guilty of Providing Inappropriate Treatment: MPTS |url=https://www.medscape.co.uk/viewarticle/leading-oncologist-guilty-misconduct-mpts-2021a1001ygw |access-date=2022-05-25 |website=Medscape UK |language=en|first=Ian|last=Leonard}} The case focused on whether Stebbing had prescribed inappropriate courses of treatment in patients whose cancers were too advanced to benefit from the treatment.{{cite web | url=https://blogs.bmj.com/medical-ethics/2022/11/13/saviour-or-sinner-why-the-case-of-justin-stebbing-matters/ | title="Saviour or Sinner?" Why the case of Justin Stebbing matters | date=13 November 2022 |first1=Johnna|last1=Wellesley|first2=Emma|last2=Tumilty|publisher=British Medical Journal}}

After initially denying all complaints against him, Stebbing eventually admitted 30 of the 36 charges, and was found guilty of another three by a Medical Practitioners Tribunal Service misconduct hearing. A number of Stebbing's patients and their families supported him, saying his "aggressive treatments" brought hope. However, he was found to have inappropriately treated patients given their poor prognosis, overstated benefits of treatment, failed to gain informed consent by not discussing the risks and benefits, and failed to maintain proper records.

The GMG suspended Stebbing from the UK medical register for nine months,{{Cite journal |last=Dyer |first=Clare |date=2021-12-21 |title=Oncologist with "cavalier attitude" to treatment is suspended for nine months after patients defend his practice |url=https://www.bmj.com/lookup/doi/10.1136/bmj.n3130 |journal=BMJ |volume=375 |language=en |pages=n3130 |doi=10.1136/bmj.n3130 |pmid=34933876 |issn=1756-1833}} with the disciplinary panel finding he had "breached the very core of the Hippocratic oath." However, he was not struck off, after the panel considered mitigating factors and an "unprecedented number" of testimonials to his clinical competence from former patients, family members of patients, and colleagues, finding it in the public interest to allow Stebbing to return to practice "as soon as possible".

Stebbing has combined his medical career with investing, and he has worked with Atticus Capital, Lansdowne Partners, Vitruvian Partners and Chaired the Board of BB Healthcare Trust.{{cite web | title=Team | website=Vitruvian Partners | url=https://www.vitruvianpartners.com/team | access-date=2025-04-17}}{{Cite web |date=2018-02-14 |title=BB Healthcare Trust delivers as it comfortably beats its benchmark |url=https://www.proactiveinvestors.co.uk/companies/news/191621/bb-healthcare-trust-delivers-as-it-comfortably-beats-its-benchmark-191621.html |access-date=2024-01-07 |website=Proactiveinvestors UK |language=en}} He is senior oncology advisor to Clinical ink,{{Cite web |title=Justin Stebbing, PhD, M.D. {{!}} Expert Advisor |url=https://www.clinicalink.com/company/leadership/justin-stebbing/ |access-date=2024-01-07 |website=Clinical ink |language=en-US}} chairs the ZephyrAI scientific advisory board,{{Cite web |date=2022-12-05 |title=Zephyr AI Announces Formation of Scientific and Medical Advisory Board |url=https://www.businesswire.com/news/home/20221205005251/en/Zephyr-AI-Announces-Formation-of-Scientific-and-Medical-Advisory-Board |access-date=2024-01-07 |website=www.businesswire.com |language=en}} and is chair of the boards of Etira{{cite web | url=https://etira.life/leadership/ | title=Leadership }} and Portage Biotech.{{cite web | title=Board of Directors Archives | website=Portage Biotech | date=2024-05-02 | url=https://www.portagebiotech.com/dt_team_category/board-of-directors/ | access-date=2025-04-17}} He is senior VP of clinical strategy and innovation{{Cite web |title=Our Company |url=https://gravitoncorp.com/company/ |access-date=2024-02-14 |website=gravitoncorp.com}} at Graviton Biosciences focusing on new treatments for fibrosis, inflammation and metabolism based on selective targeting of ROCK2.

{{Reflist}}

{{DEFAULTSORT:Stebbing, Justin}}

Category:Year of birth missing (living people)

Category:Living people

Category:Alumni of Trinity College, Oxford

Category:Alumni of Imperial College London

Category:Academics of Imperial College London

Category:Fellows of the Royal College of Physicians

Category:Fellows of the Royal College of Pathologists

Category:British oncologists

Category:NIHR Research Professors